Premium
P2‐032: Inflammatory biomarkers in the Texas Alzheimer's Research and Care Consortium (TARCC) Cohort
Author(s) -
Doody Rachelle,
Chan Wenyaw,
Barber Robert,
Ballantyne Christie,
Pavlik Valory,
O'Bryant Sid,
Darby Eveleen,
DiazArrastia Ramon,
Fairchild Thomas,
Royall Donald,
Adams Perrie
Publication year - 2011
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2011.05.922
Subject(s) - medicine , diabetes mellitus , myocardial infarction , body mass index , cohort , biomarker , stroke (engine) , heart failure , statin , cardiology , endocrinology , mechanical engineering , biochemistry , chemistry , engineering
sex and body mass index (BMI) and also examined interaction between CVDE and each biomarker separately. Results: Mean (SD) LpPla2 was 297 (71.6) in AD cases and 281 (65.6) in controls, and mean (SD) homocysteine was 16 (9.0) in AD cases, and 13 (5.0) in controls. Both biomarkers significantly predicted case-control status in unadjusted and adjusted models (p1⁄4 0.005 for LpPla2, adjusted; p1⁄4 0.009 homocysteine, adjusted), with higher levels associated with AD. There was no significant interaction between the effects of the two biomarkers. The interaction between CVDE and LpPla2 was significant.Conclusions:LpPla2 levels were higher in AD cases compared to controls, and may be an independent risk factor for AD. Once the disease is established, the predictive value of this biomarker was independent of homocysteine levels, which were elevated in AD cases as expected. The effect of LpPla2 on differentiating cases and controls was enhanced in patients who also had cardiovascular disease or its risk factors.